nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Estradiol—prostate cancer	0.211	0.605	CbGbCtD
Raltegravir—UGT1A1—Etoposide—prostate cancer	0.138	0.395	CbGbCtD
Raltegravir—UGT1A1—urine—prostate cancer	0.0201	0.221	CbGeAlD
Raltegravir—CCR1—prostate gland—prostate cancer	0.0176	0.193	CbGeAlD
Raltegravir—CCR1—seminal vesicle—prostate cancer	0.0149	0.163	CbGeAlD
Raltegravir—CCR1—urethra—prostate cancer	0.0118	0.129	CbGeAlD
Raltegravir—CCR1—bone marrow—prostate cancer	0.00905	0.0994	CbGeAlD
Raltegravir—UGT1A1—prostate gland—prostate cancer	0.00722	0.0793	CbGeAlD
Raltegravir—CCR1—lymph node—prostate cancer	0.00561	0.0616	CbGeAlD
Raltegravir—UGT1A1—renal system—prostate cancer	0.00492	0.054	CbGeAlD
Raltegravir—UGT1A1—Biological oxidations—CYP17A1—prostate cancer	0.000212	0.00118	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HSPA1A—prostate cancer	0.00021	0.00118	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP17A1—prostate cancer	0.000209	0.00117	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ADRB2—prostate cancer	0.000206	0.00115	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NCOA2—prostate cancer	0.000202	0.00113	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—VAV3—prostate cancer	0.000201	0.00113	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PRKCQ—prostate cancer	0.000199	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GNRH1—prostate cancer	0.000198	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VIP—prostate cancer	0.000198	0.00111	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—EGR1—prostate cancer	0.000197	0.0011	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GGT1—prostate cancer	0.000197	0.0011	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ITPR1—prostate cancer	0.000195	0.00109	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—prostate cancer	0.000192	0.00107	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LPAR1—prostate cancer	0.000192	0.00107	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRP—prostate cancer	0.000192	0.00107	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PLCB2—prostate cancer	0.00019	0.00106	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LRP2—prostate cancer	0.00019	0.00106	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP2E1—prostate cancer	0.000188	0.00105	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ADRB2—prostate cancer	0.000187	0.00105	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—prostate cancer	0.000186	0.00104	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—P4HB—prostate cancer	0.000186	0.00104	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CX3CL1—prostate cancer	0.000186	0.00104	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2E1—prostate cancer	0.000185	0.00104	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—RXRA—prostate cancer	0.000184	0.00103	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—VAV3—prostate cancer	0.000183	0.00102	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIST1H2BG—prostate cancer	0.000183	0.00102	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP3A4—prostate cancer	0.000181	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDE4D—prostate cancer	0.000181	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRB7—prostate cancer	0.000181	0.00101	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP3A4—prostate cancer	0.000179	0.001	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP1B1—prostate cancer	0.000178	0.000997	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ITPR1—prostate cancer	0.000177	0.000991	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—prostate cancer	0.000177	0.000989	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFBR2—prostate cancer	0.000177	0.000989	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIST1H4H—prostate cancer	0.000176	0.000987	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—prostate cancer	0.000176	0.000986	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1B1—prostate cancer	0.000176	0.000983	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GGT1—prostate cancer	0.000173	0.000966	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GNG5—prostate cancer	0.000172	0.000963	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NCOA1—prostate cancer	0.00017	0.000951	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP19A1—prostate cancer	0.000167	0.000937	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—prostate cancer	0.000167	0.000933	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP19A1—prostate cancer	0.000165	0.000924	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—prostate cancer	0.000163	0.000915	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—prostate cancer	0.000162	0.000909	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—RXRA—prostate cancer	0.000162	0.000905	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—COMT—prostate cancer	0.000156	0.000871	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—prostate cancer	0.000155	0.000867	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—COMT—prostate cancer	0.000154	0.000859	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—prostate cancer	0.000153	0.000855	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTHLH—prostate cancer	0.00015	0.000839	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFBR1—prostate cancer	0.00015	0.000839	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKR1C3—prostate cancer	0.000147	0.000825	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKACB—prostate cancer	0.000147	0.000821	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PPP3CA—prostate cancer	0.000143	0.0008	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—THBS1—prostate cancer	0.000143	0.0008	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—prostate cancer	0.000142	0.000797	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ANXA1—prostate cancer	0.000141	0.000789	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—prostate cancer	0.00014	0.000786	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKCZ—prostate cancer	0.000138	0.000774	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—prostate cancer	0.000135	0.000757	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP1A1—prostate cancer	0.000135	0.000756	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR4—prostate cancer	0.000134	0.000748	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PARP1—prostate cancer	0.000134	0.000748	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HAO1—prostate cancer	0.000133	0.000746	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1A1—prostate cancer	0.000133	0.000745	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CALCA—prostate cancer	0.000132	0.000739	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL12—prostate cancer	0.000129	0.000721	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—prostate cancer	0.000123	0.000687	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP9—prostate cancer	0.000121	0.000679	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—prostate cancer	0.000119	0.000665	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NGFR—prostate cancer	0.000118	0.000658	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKCQ—prostate cancer	0.000118	0.000658	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAP3K7—prostate cancer	0.000116	0.00065	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF10—prostate cancer	0.000112	0.000625	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ADRB2—prostate cancer	0.000111	0.000619	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—JAK2—prostate cancer	0.000109	0.000611	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAP2K1—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TST—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CBR1—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CSAD—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ADI1—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GRHL1—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PSAT1—prostate cancer	0.000109	0.000608	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—prostate cancer	0.000108	0.000604	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VAV3—prostate cancer	0.000108	0.000604	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFBR2—prostate cancer	0.000106	0.000595	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ITPR1—prostate cancer	0.000105	0.000585	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—prostate cancer	0.000104	0.00058	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—UGT2B15—prostate cancer	0.000101	0.000565	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—UGT2B17—prostate cancer	0.000101	0.000565	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CKMT2—prostate cancer	0.000101	0.000565	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GRHPR—prostate cancer	0.000101	0.000565	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1R—prostate cancer	0.0001	0.00056	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—prostate cancer	9.96e-05	0.000557	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—JAK2—prostate cancer	9.91e-05	0.000554	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LPL—prostate cancer	9.59e-05	0.000537	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—prostate cancer	9.51e-05	0.000533	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFRB—prostate cancer	9.5e-05	0.000532	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM3—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AOX1—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MBTPS1—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—RFK—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PGAM2—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NAGLU—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SULT2B1—prostate cancer	9.49e-05	0.000531	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—prostate cancer	9.41e-05	0.000527	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ITGB3—prostate cancer	9.26e-05	0.000518	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—prostate cancer	9.04e-05	0.000506	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AMACR—prostate cancer	9e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP3A43—prostate cancer	9e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NAT1—prostate cancer	9e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—DEGS1—prostate cancer	9e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SRD5A2—prostate cancer	9e-05	0.000504	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB3—prostate cancer	8.98e-05	0.000503	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR2—prostate cancer	8.97e-05	0.000502	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2—prostate cancer	8.64e-05	0.000484	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—prostate cancer	8.61e-05	0.000482	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HSD17B1—prostate cancer	8.58e-05	0.000481	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIF1A—prostate cancer	8.23e-05	0.000461	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LEP—prostate cancer	8.04e-05	0.00045	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CAV1—prostate cancer	7.96e-05	0.000446	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KDR—prostate cancer	7.87e-05	0.000441	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ESR1—prostate cancer	7.67e-05	0.000429	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPGD—prostate cancer	7.65e-05	0.000428	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—B4GALT4—prostate cancer	7.65e-05	0.000428	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BAD—prostate cancer	7.49e-05	0.000419	CbGpPWpGaD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	7.32e-05	0.000192	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—prostate cancer	7.25e-05	0.00019	CcSEcCtD
Raltegravir—Infection—Capecitabine—prostate cancer	7.25e-05	0.00019	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APC—prostate cancer	7.25e-05	0.000406	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—prostate cancer	7.25e-05	0.000406	CbGpPWpGaD
Raltegravir—Neuropathy peripheral—Doxorubicin—prostate cancer	7.23e-05	0.00019	CcSEcCtD
Raltegravir—Urticaria—Etoposide—prostate cancer	7.21e-05	0.000189	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—TNFRSF21—prostate cancer	7.19e-05	0.000403	CbGpPWpGaD
Raltegravir—Malaise—Prednisone—prostate cancer	7.19e-05	0.000189	CcSEcCtD
Raltegravir—Abdominal pain—Etoposide—prostate cancer	7.17e-05	0.000188	CcSEcCtD
Raltegravir—Body temperature increased—Etoposide—prostate cancer	7.17e-05	0.000188	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IRS1—prostate cancer	7.17e-05	0.000401	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGF—prostate cancer	7.17e-05	0.000401	CbGpPWpGaD
Raltegravir—Nervous system disorder—Capecitabine—prostate cancer	7.16e-05	0.000188	CcSEcCtD
Raltegravir—Vertigo—Prednisone—prostate cancer	7.16e-05	0.000188	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—prostate cancer	7.16e-05	0.000188	CcSEcCtD
Raltegravir—Thrombocytopenia—Capecitabine—prostate cancer	7.15e-05	0.000188	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—prostate cancer	7.12e-05	0.000187	CcSEcCtD
Raltegravir—Skin disorder—Capecitabine—prostate cancer	7.09e-05	0.000186	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—prostate cancer	7.07e-05	0.000186	CcSEcCtD
Raltegravir—Hyperhidrosis—Capecitabine—prostate cancer	7.06e-05	0.000185	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—prostate cancer	7.05e-05	0.000185	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—prostate cancer	7.04e-05	0.000185	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—prostate cancer	7.04e-05	0.000185	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—prostate cancer	7.02e-05	0.000184	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP7B1—prostate cancer	7e-05	0.000392	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTAP—prostate cancer	7e-05	0.000392	CbGpPWpGaD
Raltegravir—Hepatobiliary disease—Doxorubicin—prostate cancer	6.98e-05	0.000183	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—prostate cancer	6.96e-05	0.000183	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GSK3B—prostate cancer	6.96e-05	0.00039	CbGpPWpGaD
Raltegravir—Nausea—Estradiol—prostate cancer	6.95e-05	0.000183	CcSEcCtD
Raltegravir—Vomiting—Mitoxantrone—prostate cancer	6.94e-05	0.000182	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—prostate cancer	6.9e-05	0.000181	CcSEcCtD
Raltegravir—Hypertension—Prednisone—prostate cancer	6.88e-05	0.000181	CcSEcCtD
Raltegravir—Rash—Mitoxantrone—prostate cancer	6.88e-05	0.000181	CcSEcCtD
Raltegravir—Dermatitis—Mitoxantrone—prostate cancer	6.87e-05	0.00018	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.87e-05	0.00018	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—INS—prostate cancer	6.87e-05	0.000384	CbGpPWpGaD
Raltegravir—Headache—Mitoxantrone—prostate cancer	6.83e-05	0.000179	CcSEcCtD
Raltegravir—Insomnia—Docetaxel—prostate cancer	6.82e-05	0.000179	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SULT1E1—prostate cancer	6.82e-05	0.000382	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SRD5A1—prostate cancer	6.82e-05	0.000382	CbGpPWpGaD
Raltegravir—Arthralgia—Prednisone—prostate cancer	6.78e-05	0.000178	CcSEcCtD
Raltegravir—Myalgia—Prednisone—prostate cancer	6.78e-05	0.000178	CcSEcCtD
Raltegravir—Paraesthesia—Docetaxel—prostate cancer	6.77e-05	0.000178	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—prostate cancer	6.77e-05	0.000178	CcSEcCtD
Raltegravir—Anxiety—Prednisone—prostate cancer	6.76e-05	0.000177	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.74e-05	0.000177	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CREBBP—prostate cancer	6.72e-05	0.000376	CbGpPWpGaD
Raltegravir—Somnolence—Docetaxel—prostate cancer	6.7e-05	0.000176	CcSEcCtD
Raltegravir—Discomfort—Prednisone—prostate cancer	6.7e-05	0.000176	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—prostate cancer	6.69e-05	0.000176	CcSEcCtD
Raltegravir—Hypersensitivity—Etoposide—prostate cancer	6.69e-05	0.000175	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—prostate cancer	6.68e-05	0.000175	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.65e-05	0.000175	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—prostate cancer	6.64e-05	0.000174	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IGF1—prostate cancer	6.64e-05	0.000372	CbGpPWpGaD
Raltegravir—Dyspepsia—Docetaxel—prostate cancer	6.64e-05	0.000174	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—prostate cancer	6.62e-05	0.000174	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—prostate cancer	6.62e-05	0.00037	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—prostate cancer	6.61e-05	0.00037	CbGpPWpGaD
Raltegravir—Insomnia—Capecitabine—prostate cancer	6.6e-05	0.000173	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—prostate cancer	6.59e-05	0.000173	CcSEcCtD
Raltegravir—Paraesthesia—Capecitabine—prostate cancer	6.56e-05	0.000172	CcSEcCtD
Raltegravir—Decreased appetite—Docetaxel—prostate cancer	6.56e-05	0.000172	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—prostate cancer	6.54e-05	0.000172	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—prostate cancer	6.53e-05	0.000171	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Docetaxel—prostate cancer	6.51e-05	0.000171	CcSEcCtD
Raltegravir—Asthenia—Etoposide—prostate cancer	6.51e-05	0.000171	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—prostate cancer	6.51e-05	0.000171	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ACSL4—prostate cancer	6.51e-05	0.000364	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HSD17B3—prostate cancer	6.51e-05	0.000364	CbGpPWpGaD
Raltegravir—Fatigue—Docetaxel—prostate cancer	6.5e-05	0.000171	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—prostate cancer	6.5e-05	0.00017	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—prostate cancer	6.49e-05	0.00017	CcSEcCtD
Raltegravir—Nausea—Mitoxantrone—prostate cancer	6.48e-05	0.00017	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—prostate cancer	6.47e-05	0.00017	CcSEcCtD
Raltegravir—Infection—Prednisone—prostate cancer	6.46e-05	0.00017	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—prostate cancer	6.45e-05	0.000169	CcSEcCtD
Raltegravir—Pain—Docetaxel—prostate cancer	6.45e-05	0.000169	CcSEcCtD
Raltegravir—Constipation—Docetaxel—prostate cancer	6.45e-05	0.000169	CcSEcCtD
Raltegravir—Dyspepsia—Capecitabine—prostate cancer	6.43e-05	0.000169	CcSEcCtD
Raltegravir—Chills—Epirubicin—prostate cancer	6.42e-05	0.000169	CcSEcCtD
Raltegravir—Pruritus—Etoposide—prostate cancer	6.42e-05	0.000168	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAP2K1—prostate cancer	6.42e-05	0.000359	CbGpPWpGaD
Raltegravir—Visual impairment—Doxorubicin—prostate cancer	6.38e-05	0.000168	CcSEcCtD
Raltegravir—Nervous system disorder—Prednisone—prostate cancer	6.38e-05	0.000167	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—prostate cancer	6.38e-05	0.000357	CbGpPWpGaD
Raltegravir—Decreased appetite—Capecitabine—prostate cancer	6.35e-05	0.000167	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—prostate cancer	6.33e-05	0.000166	CcSEcCtD
Raltegravir—Skin disorder—Prednisone—prostate cancer	6.32e-05	0.000166	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—prostate cancer	6.32e-05	0.000353	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SERPINE1—prostate cancer	6.31e-05	0.000353	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Capecitabine—prostate cancer	6.3e-05	0.000165	CcSEcCtD
Raltegravir—Fatigue—Capecitabine—prostate cancer	6.29e-05	0.000165	CcSEcCtD
Raltegravir—Hyperhidrosis—Prednisone—prostate cancer	6.29e-05	0.000165	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—prostate cancer	6.27e-05	0.000165	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—prostate cancer	6.26e-05	0.000164	CcSEcCtD
Raltegravir—Pain—Capecitabine—prostate cancer	6.24e-05	0.000164	CcSEcCtD
Raltegravir—Constipation—Capecitabine—prostate cancer	6.24e-05	0.000164	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KRAS—prostate cancer	6.24e-05	0.000349	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ARG2—prostate cancer	6.24e-05	0.000349	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—UMPS—prostate cancer	6.24e-05	0.000349	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PHGDH—prostate cancer	6.24e-05	0.000349	CbGpPWpGaD
Raltegravir—Malnutrition—Epirubicin—prostate cancer	6.23e-05	0.000164	CcSEcCtD
Raltegravir—Erythema—Epirubicin—prostate cancer	6.23e-05	0.000164	CcSEcCtD
Raltegravir—Feeling abnormal—Docetaxel—prostate cancer	6.21e-05	0.000163	CcSEcCtD
Raltegravir—Diarrhoea—Etoposide—prostate cancer	6.21e-05	0.000163	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—prostate cancer	6.19e-05	0.000162	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—prostate cancer	6.18e-05	0.000162	CcSEcCtD
Raltegravir—Gastrointestinal pain—Docetaxel—prostate cancer	6.17e-05	0.000162	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—prostate cancer	6.15e-05	0.000161	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—prostate cancer	6.14e-05	0.000161	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—LDHB—prostate cancer	6.12e-05	0.000342	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF2—prostate cancer	6.11e-05	0.000342	CbGpPWpGaD
Raltegravir—Dysgeusia—Epirubicin—prostate cancer	6.1e-05	0.00016	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—prostate cancer	6.05e-05	0.000159	CcSEcCtD
Raltegravir—Back pain—Epirubicin—prostate cancer	6.03e-05	0.000158	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NOS3—prostate cancer	6.02e-05	0.000337	CbGpPWpGaD
Raltegravir—Feeling abnormal—Capecitabine—prostate cancer	6.02e-05	0.000158	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—prostate cancer	6.01e-05	0.000158	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP3A5—prostate cancer	6e-05	0.000336	CbGpPWpGaD
Raltegravir—Dizziness—Etoposide—prostate cancer	6e-05	0.000157	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—prostate cancer	5.98e-05	0.000157	CcSEcCtD
Raltegravir—Gastrointestinal pain—Capecitabine—prostate cancer	5.97e-05	0.000157	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—prostate cancer	5.97e-05	0.000157	CcSEcCtD
Raltegravir—Abdominal pain—Docetaxel—prostate cancer	5.96e-05	0.000156	CcSEcCtD
Raltegravir—Body temperature increased—Docetaxel—prostate cancer	5.96e-05	0.000156	CcSEcCtD
Raltegravir—Chills—Doxorubicin—prostate cancer	5.94e-05	0.000156	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Prednisone—prostate cancer	5.93e-05	0.000156	CcSEcCtD
Raltegravir—Insomnia—Prednisone—prostate cancer	5.88e-05	0.000154	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—prostate cancer	5.85e-05	0.000154	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—JAK2—prostate cancer	5.85e-05	0.000328	CbGpPWpGaD
Raltegravir—Paraesthesia—Prednisone—prostate cancer	5.84e-05	0.000153	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—prostate cancer	5.8e-05	0.000152	CcSEcCtD
Raltegravir—Urticaria—Capecitabine—prostate cancer	5.8e-05	0.000152	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—TCN2—prostate cancer	5.8e-05	0.000325	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PDHA1—prostate cancer	5.8e-05	0.000325	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA3—prostate cancer	5.8e-05	0.000325	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—UCP3—prostate cancer	5.8e-05	0.000325	CbGpPWpGaD
Raltegravir—Ill-defined disorder—Epirubicin—prostate cancer	5.78e-05	0.000152	CcSEcCtD
Raltegravir—Body temperature increased—Capecitabine—prostate cancer	5.77e-05	0.000151	CcSEcCtD
Raltegravir—Abdominal pain—Capecitabine—prostate cancer	5.77e-05	0.000151	CcSEcCtD
Raltegravir—Vomiting—Etoposide—prostate cancer	5.77e-05	0.000151	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—prostate cancer	5.77e-05	0.000151	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—prostate cancer	5.77e-05	0.000151	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—prostate cancer	5.76e-05	0.000151	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—prostate cancer	5.74e-05	0.000321	CbGpPWpGaD
Raltegravir—Agitation—Epirubicin—prostate cancer	5.73e-05	0.00015	CcSEcCtD
Raltegravir—Dyspepsia—Prednisone—prostate cancer	5.72e-05	0.00015	CcSEcCtD
Raltegravir—Rash—Etoposide—prostate cancer	5.72e-05	0.00015	CcSEcCtD
Raltegravir—Dermatitis—Etoposide—prostate cancer	5.72e-05	0.00015	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MDM2—prostate cancer	5.71e-05	0.00032	CbGpPWpGaD
Raltegravir—Headache—Etoposide—prostate cancer	5.68e-05	0.000149	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—prostate cancer	5.68e-05	0.000149	CcSEcCtD
Raltegravir—Decreased appetite—Prednisone—prostate cancer	5.65e-05	0.000148	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—prostate cancer	5.65e-05	0.000148	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB2—prostate cancer	5.63e-05	0.000315	CbGpPWpGaD
Raltegravir—Malaise—Epirubicin—prostate cancer	5.62e-05	0.000148	CcSEcCtD
Raltegravir—Fatigue—Prednisone—prostate cancer	5.61e-05	0.000147	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—prostate cancer	5.6e-05	0.000147	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—prostate cancer	5.6e-05	0.000147	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—prostate cancer	5.58e-05	0.000146	CcSEcCtD
Raltegravir—Constipation—Prednisone—prostate cancer	5.56e-05	0.000146	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—prostate cancer	5.56e-05	0.000311	CbGpPWpGaD
Raltegravir—Hypersensitivity—Docetaxel—prostate cancer	5.56e-05	0.000146	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC22A3—prostate cancer	5.53e-05	0.00031	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HSD3B1—prostate cancer	5.53e-05	0.00031	CbGpPWpGaD
Raltegravir—Palpitations—Epirubicin—prostate cancer	5.51e-05	0.000145	CcSEcCtD
Raltegravir—Cough—Epirubicin—prostate cancer	5.44e-05	0.000143	CcSEcCtD
Raltegravir—Asthenia—Docetaxel—prostate cancer	5.41e-05	0.000142	CcSEcCtD
Raltegravir—Nausea—Etoposide—prostate cancer	5.39e-05	0.000141	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—prostate cancer	5.38e-05	0.000141	CcSEcCtD
Raltegravir—Hypersensitivity—Capecitabine—prostate cancer	5.38e-05	0.000141	CcSEcCtD
Raltegravir—Feeling abnormal—Prednisone—prostate cancer	5.36e-05	0.000141	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—prostate cancer	5.35e-05	0.00014	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL8—prostate cancer	5.34e-05	0.000299	CbGpPWpGaD
Raltegravir—Pruritus—Docetaxel—prostate cancer	5.34e-05	0.00014	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—prostate cancer	5.33e-05	0.00014	CcSEcCtD
Raltegravir—Gastrointestinal pain—Prednisone—prostate cancer	5.32e-05	0.00014	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—prostate cancer	5.31e-05	0.000139	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—prostate cancer	5.31e-05	0.000139	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—prostate cancer	5.31e-05	0.000139	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—TBXAS1—prostate cancer	5.3e-05	0.000297	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA4—prostate cancer	5.3e-05	0.000297	CbGpPWpGaD
Raltegravir—Agitation—Doxorubicin—prostate cancer	5.3e-05	0.000139	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—prostate cancer	5.29e-05	0.000139	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.27e-05	0.000138	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—prostate cancer	5.24e-05	0.000138	CcSEcCtD
Raltegravir—Asthenia—Capecitabine—prostate cancer	5.24e-05	0.000137	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CDKN1B—prostate cancer	5.22e-05	0.000292	CbGpPWpGaD
Raltegravir—Malaise—Doxorubicin—prostate cancer	5.2e-05	0.000136	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—prostate cancer	5.19e-05	0.000136	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—prostate cancer	5.18e-05	0.000136	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTA2—prostate cancer	5.17e-05	0.000289	CbGpPWpGaD
Raltegravir—Urticaria—Prednisone—prostate cancer	5.17e-05	0.000136	CcSEcCtD
Raltegravir—Pruritus—Capecitabine—prostate cancer	5.17e-05	0.000136	CcSEcCtD
Raltegravir—Diarrhoea—Docetaxel—prostate cancer	5.16e-05	0.000135	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—prostate cancer	5.16e-05	0.000289	CbGpPWpGaD
Raltegravir—Abdominal pain—Prednisone—prostate cancer	5.14e-05	0.000135	CcSEcCtD
Raltegravir—Body temperature increased—Prednisone—prostate cancer	5.14e-05	0.000135	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—prostate cancer	5.13e-05	0.000135	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CASP3—prostate cancer	5.11e-05	0.000286	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SULT1A1—prostate cancer	5.11e-05	0.000286	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCG5—prostate cancer	5.11e-05	0.000286	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—prostate cancer	5.1e-05	0.000286	CbGpPWpGaD
Raltegravir—Palpitations—Doxorubicin—prostate cancer	5.1e-05	0.000134	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL6—prostate cancer	5.08e-05	0.000284	CbGpPWpGaD
Raltegravir—Infection—Epirubicin—prostate cancer	5.05e-05	0.000133	CcSEcCtD
Raltegravir—Cough—Doxorubicin—prostate cancer	5.03e-05	0.000132	CcSEcCtD
Raltegravir—Diarrhoea—Capecitabine—prostate cancer	5e-05	0.000131	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—prostate cancer	4.99e-05	0.000131	CcSEcCtD
Raltegravir—Dizziness—Docetaxel—prostate cancer	4.99e-05	0.000131	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTA1—prostate cancer	4.99e-05	0.000279	CbGpPWpGaD
Raltegravir—Thrombocytopenia—Epirubicin—prostate cancer	4.98e-05	0.000131	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—prostate cancer	4.98e-05	0.000131	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCND1—prostate cancer	4.98e-05	0.000278	CbGpPWpGaD
Raltegravir—Skin disorder—Epirubicin—prostate cancer	4.94e-05	0.00013	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HSD3B2—prostate cancer	4.93e-05	0.000276	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTO1—prostate cancer	4.93e-05	0.000276	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NAT2—prostate cancer	4.93e-05	0.000276	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNB1—prostate cancer	4.93e-05	0.000276	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Epirubicin—prostate cancer	4.92e-05	0.000129	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—prostate cancer	4.91e-05	0.000129	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—prostate cancer	4.91e-05	0.000129	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—prostate cancer	4.91e-05	0.000129	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—prostate cancer	4.89e-05	0.000128	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.88e-05	0.000128	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—prostate cancer	4.85e-05	0.000127	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MMP9—prostate cancer	4.83e-05	0.00027	CbGpPWpGaD
Raltegravir—Dizziness—Capecitabine—prostate cancer	4.83e-05	0.000127	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—prostate cancer	4.81e-05	0.000269	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—prostate cancer	4.8e-05	0.000269	CbGpPWpGaD
Raltegravir—Dry mouth—Doxorubicin—prostate cancer	4.8e-05	0.000126	CcSEcCtD
Raltegravir—Vomiting—Docetaxel—prostate cancer	4.79e-05	0.000126	CcSEcCtD
Raltegravir—Hypersensitivity—Prednisone—prostate cancer	4.79e-05	0.000126	CcSEcCtD
Raltegravir—Rash—Docetaxel—prostate cancer	4.75e-05	0.000125	CcSEcCtD
Raltegravir—Dermatitis—Docetaxel—prostate cancer	4.75e-05	0.000125	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—prostate cancer	4.75e-05	0.000125	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—LRP2—prostate cancer	4.73e-05	0.000265	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLCB2—prostate cancer	4.73e-05	0.000265	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2C18—prostate cancer	4.73e-05	0.000265	CbGpPWpGaD
Raltegravir—Headache—Docetaxel—prostate cancer	4.72e-05	0.000124	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AKT1—prostate cancer	4.69e-05	0.000262	CbGpPWpGaD
Raltegravir—Infection—Doxorubicin—prostate cancer	4.68e-05	0.000123	CcSEcCtD
Raltegravir—Asthenia—Prednisone—prostate cancer	4.67e-05	0.000122	CcSEcCtD
Raltegravir—Vomiting—Capecitabine—prostate cancer	4.64e-05	0.000122	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—P4HB—prostate cancer	4.64e-05	0.000259	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.63e-05	0.000122	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—prostate cancer	4.62e-05	0.000121	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—prostate cancer	4.61e-05	0.000121	CcSEcCtD
Raltegravir—Rash—Capecitabine—prostate cancer	4.6e-05	0.000121	CcSEcCtD
Raltegravir—Pruritus—Prednisone—prostate cancer	4.6e-05	0.000121	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—prostate cancer	4.6e-05	0.000121	CcSEcCtD
Raltegravir—Dermatitis—Capecitabine—prostate cancer	4.6e-05	0.000121	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EP300—prostate cancer	4.58e-05	0.000256	CbGpPWpGaD
Raltegravir—Headache—Capecitabine—prostate cancer	4.57e-05	0.00012	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—prostate cancer	4.57e-05	0.00012	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—prostate cancer	4.57e-05	0.00012	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—prostate cancer	4.55e-05	0.000119	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—prostate cancer	4.52e-05	0.000119	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC22A1—prostate cancer	4.51e-05	0.000252	CbGpPWpGaD
Raltegravir—Nausea—Docetaxel—prostate cancer	4.48e-05	0.000118	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—prostate cancer	4.48e-05	0.000118	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SRC—prostate cancer	4.45e-05	0.000249	CbGpPWpGaD
Raltegravir—Diarrhoea—Prednisone—prostate cancer	4.45e-05	0.000117	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—prostate cancer	4.42e-05	0.000116	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SULT2A1—prostate cancer	4.39e-05	0.000246	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Epirubicin—prostate cancer	4.39e-05	0.000115	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—prostate cancer	4.39e-05	0.000115	CcSEcCtD
Raltegravir—Pain—Epirubicin—prostate cancer	4.35e-05	0.000114	CcSEcCtD
Raltegravir—Constipation—Epirubicin—prostate cancer	4.35e-05	0.000114	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VEGFA—prostate cancer	4.34e-05	0.000243	CbGpPWpGaD
Raltegravir—Nausea—Capecitabine—prostate cancer	4.34e-05	0.000114	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—MED12—prostate cancer	4.32e-05	0.000242	CbGpPWpGaD
Raltegravir—Dizziness—Prednisone—prostate cancer	4.3e-05	0.000113	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—STAT3—prostate cancer	4.3e-05	0.00024	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNG5—prostate cancer	4.29e-05	0.00024	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.29e-05	0.000113	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—prostate cancer	4.26e-05	0.000112	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—prostate cancer	4.23e-05	0.000111	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—prostate cancer	4.19e-05	0.00011	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—prostate cancer	4.18e-05	0.00011	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—prostate cancer	4.16e-05	0.000109	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—prostate cancer	4.14e-05	0.000109	CcSEcCtD
Raltegravir—Vomiting—Prednisone—prostate cancer	4.14e-05	0.000109	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA3—prostate cancer	4.13e-05	0.000231	CbGpPWpGaD
Raltegravir—Rash—Prednisone—prostate cancer	4.1e-05	0.000108	CcSEcCtD
Raltegravir—Dermatitis—Prednisone—prostate cancer	4.1e-05	0.000108	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—prostate cancer	4.09e-05	0.000107	CcSEcCtD
Raltegravir—Headache—Prednisone—prostate cancer	4.07e-05	0.000107	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.06e-05	0.000107	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—prostate cancer	4.06e-05	0.000106	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—prostate cancer	4.04e-05	0.000106	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—prostate cancer	4.02e-05	0.000106	CcSEcCtD
Raltegravir—Pain—Doxorubicin—prostate cancer	4.02e-05	0.000106	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—prostate cancer	4.02e-05	0.000106	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—prostate cancer	4.02e-05	0.000106	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—prostate cancer	3.99e-05	0.000223	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—prostate cancer	3.98e-05	0.000223	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPGDS—prostate cancer	3.94e-05	0.000221	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2C19—prostate cancer	3.92e-05	0.000219	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGFR—prostate cancer	3.9e-05	0.000218	CbGpPWpGaD
Raltegravir—Feeling abnormal—Doxorubicin—prostate cancer	3.88e-05	0.000102	CcSEcCtD
Raltegravir—Nausea—Prednisone—prostate cancer	3.86e-05	0.000101	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—prostate cancer	3.85e-05	0.000101	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTT1—prostate cancer	3.82e-05	0.000214	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ACHE—prostate cancer	3.82e-05	0.000214	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2A6—prostate cancer	3.78e-05	0.000212	CbGpPWpGaD
Raltegravir—Hypersensitivity—Epirubicin—prostate cancer	3.75e-05	9.84e-05	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—prostate cancer	3.74e-05	9.81e-05	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—prostate cancer	3.72e-05	9.76e-05	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—prostate cancer	3.72e-05	9.76e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KRAS—prostate cancer	3.69e-05	0.000206	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKR1C3—prostate cancer	3.68e-05	0.000206	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PRKACB—prostate cancer	3.66e-05	0.000205	CbGpPWpGaD
Raltegravir—Asthenia—Epirubicin—prostate cancer	3.65e-05	9.58e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP17A1—prostate cancer	3.62e-05	0.000203	CbGpPWpGaD
Raltegravir—Pruritus—Epirubicin—prostate cancer	3.6e-05	9.44e-05	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—prostate cancer	3.48e-05	9.13e-05	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—prostate cancer	3.47e-05	9.1e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA2—prostate cancer	3.45e-05	0.000193	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—prostate cancer	3.39e-05	0.00019	CbGpPWpGaD
Raltegravir—Asthenia—Doxorubicin—prostate cancer	3.38e-05	8.86e-05	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—prostate cancer	3.36e-05	8.83e-05	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—prostate cancer	3.33e-05	8.74e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC5A5—prostate cancer	3.29e-05	0.000184	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—prostate cancer	3.28e-05	0.000183	CbGpPWpGaD
Raltegravir—Vomiting—Epirubicin—prostate cancer	3.23e-05	8.49e-05	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—prostate cancer	3.22e-05	8.45e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP2E1—prostate cancer	3.21e-05	0.00018	CbGpPWpGaD
Raltegravir—Rash—Epirubicin—prostate cancer	3.21e-05	8.42e-05	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—prostate cancer	3.2e-05	8.41e-05	CcSEcCtD
Raltegravir—Headache—Epirubicin—prostate cancer	3.19e-05	8.36e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NQO1—prostate cancer	3.18e-05	0.000178	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TH—prostate cancer	3.13e-05	0.000175	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—prostate cancer	3.11e-05	8.17e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP3A4—prostate cancer	3.1e-05	0.000173	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1B1—prostate cancer	3.05e-05	0.00017	CbGpPWpGaD
Raltegravir—Nausea—Epirubicin—prostate cancer	3.02e-05	7.93e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL6—prostate cancer	3e-05	0.000168	CbGpPWpGaD
Raltegravir—Vomiting—Doxorubicin—prostate cancer	2.99e-05	7.85e-05	CcSEcCtD
Raltegravir—Rash—Doxorubicin—prostate cancer	2.97e-05	7.79e-05	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—prostate cancer	2.96e-05	7.78e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GGT1—prostate cancer	2.95e-05	0.000165	CbGpPWpGaD
Raltegravir—Headache—Doxorubicin—prostate cancer	2.95e-05	7.74e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA1—prostate cancer	2.91e-05	0.000163	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP19A1—prostate cancer	2.86e-05	0.00016	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—prostate cancer	2.8e-05	7.34e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKT1—prostate cancer	2.77e-05	0.000155	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—RXRA—prostate cancer	2.76e-05	0.000155	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—COMT—prostate cancer	2.66e-05	0.000149	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—prostate cancer	2.65e-05	0.000148	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ITPR1—prostate cancer	2.61e-05	0.000146	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TYMS—prostate cancer	2.46e-05	0.000138	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—prostate cancer	2.44e-05	0.000136	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LPL—prostate cancer	2.39e-05	0.000134	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1A1—prostate cancer	2.31e-05	0.000129	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ERCC2—prostate cancer	2.29e-05	0.000128	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTHFR—prostate cancer	2.15e-05	0.00012	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARA—prostate cancer	2.11e-05	0.000118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAV1—prostate cancer	1.99e-05	0.000111	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—prostate cancer	1.81e-05	0.000101	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—INS—prostate cancer	1.71e-05	9.58e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CREBBP—prostate cancer	1.68e-05	9.38e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—prostate cancer	1.59e-05	8.9e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NOS3—prostate cancer	1.5e-05	8.4e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—prostate cancer	1.39e-05	7.76e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—prostate cancer	1.37e-05	7.68e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—prostate cancer	1.2e-05	6.7e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—EP300—prostate cancer	1.14e-05	6.39e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—prostate cancer	8.45e-06	4.73e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—prostate cancer	6.9e-06	3.86e-05	CbGpPWpGaD
